FDA Approved Brepocitinib for Dermatomyositis
The drug is the first oral treatment cleared for use as an add-on therapy for patients with the condition.
Updated on Oct. 14, 2026 in Arthritis
Live Poll
Do you feel that new medical treatments for rare diseases are becoming more accessible for patients?
In August 2026, the FDA approved brepocitinib as the first oral treatment indicated for patients with dermatomyositis. The drug serves as an add-on therapy for those who do not achieve sufficient disease control on their current background treatments.
Why it matters
This approval provides a new oral option for managing dermatomyositis, an inflammatory condition that can be difficult to control. It specifically targets patients who require additional support beyond their existing therapeutic regimens.
In the Phase 3 VALOR study of 241 patients, the 30 mg brepocitinib group achieved a 68% moderate response rate and a 46% major response rate, compared to 44% and 26% in the placebo group respectively.
The players
FDA
The Food and Drug Administration is the federal agency responsible for regulating food and drug safety in the United States.
The details
Brepocitinib functions as a selective tyrosine kinase 2 and Janus kinase 1 inhibitor designed to dampen the type I and type II interferon response. The study endpoints were finalized at week 52, with a least-squares mean difference of 15.3 points between the treatment and placebo arms.
Timeline
The FDA approved brepocitinib in August 2026.
Study participants demonstrated efficacy beginning at week 4.
Researchers measured final efficacy endpoints in the VALOR study at week 52.
Health Landscape
This approval follows findings from the VALOR study, which investigated the efficacy of novel JAK inhibitors in autoimmune care. The regulatory decision marks the successful conclusion of clinical endpoints previously established by the trial to evaluate treatment success.
Patients with dermatomyositis now have access to a new oral treatment option as an add-on to their existing background therapy. Those interested in this medication should consult their rheumatologist to discuss whether their current disease control meets the criteria for this addition.
The takeaway
Patients struggling with dermatomyositis may benefit from discussing this new tyrosine kinase inhibitor with their care team. Clinical data suggests that this oral add-on therapy can provide significant improvement in both moderate and major response metrics compared to standard care alone.
Further reading
For more information on current treatment trends, visit the Arthritis section.
Source note: This article includes information reported by Healio.
Live Poll
Do you feel that new medical treatments for rare diseases are becoming more accessible for patients?
